drugset / Trial / NCT04750837

Platelet Rich Plasma and Diabetic Foot Ulcer

NCT04750837

Phase 2 Completed 72 enrolled Zagazig University
RandomizedParallel-groupOpen-labelTreatment

Summary

In chronic diabetic foot ulcer, if the conventional dressing fails, new therapeutic options such as recombinant human growth factors and bioengineered skin substitutes may be beneficial, but the cost is a limiting factor. Autologous platelet rich plasma is a cost-effective method that enhances wound healing by promoting the healing process by local release of growth factors.

Timeline

Start
2020-01-16
Primary completion
2020-12-21
Completion
2021-01-20

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Platelet Rich Plasma Other / unclassified Other

Indications

No indication recorded.